2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 944

Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Abstract Number: 945

Autoantibodies to the hPOP1 and Rpp25/38 Components of the Th/to Complex Identify a Subgroup of Systemic Sclerosis (SSc) Associated Interstitial Lung Disease (ILD) and Antibodies to hPOP1 Are Associated with Reduced Survival
Abstract Number: 946

Clinical and Serological Features of Systemic Sclerosis in a Multicenter African American Cohort: Analysis of the Genome Research in African American Scleroderma Patients Clinical Database
Abstract Number: 947

Norway As a National Reference Population for Systemic Sclerosis; Preliminary Results from a Complete, Nationwide Cohort
Abstract Number: 948

Application of a Diagnostic Algorithm to Identify Inflammatory Myopathy in Systemic Sclerosis
Abstract Number: 949

Sequence Homology and Immune Reactivity between T Cell Epitopes of Related Gut Microbes and Two Novel Autoantigens Provide a Link between Microbial and Host Immunity in Patients with Rheumatoid Arthritis
Abstract Number: 950

Identification of Naturally Processed Immunodominant Topoisomerase I Epitopes in Patients with Systemic Sclerosis
Abstract Number: 951

Cross Sectional Analysis of Citrullinated-Synovial Antigen-Specific CD4+ T Cells in an RA Cohort Demonstrates Antigen Based Differences in T Cell Frequency, Phenotype and the Influence of Immunotherapy
Abstract Number: 952

Serine Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Regulator of T Lymphocyte Homeostasis In Vivo and Its Deficiency Associates with Lymphopenia in SLE Patients
Abstract Number: 953

Persistence of Pathogenic CD4 Memory T Cells Revealed through Cytometry Time of Flight in Juvenile Idiopathic Arthritic Patients with Disease Resurgence upon Withdrawal of Anti-TNFA Biologics
Abstract Number: 954

Microrna-21 Is a Critical Regulator of Autoimmunity through Promoting Effector and Metabolic Function of Pathogenic TH17 Cells
Abstract Number: 955

In Vitro Effects of CR6086, a Potent ProstaglandinE2 Subtype 4 Receptor Antagonist, on Bone Erosive Pathways
Abstract Number: 956

Inhibition of Fucosylation in Endothelial Cells Reduces Rheumatoid Arthritis Angiogenesis
Abstract Number: 957

A Disintegrin and Metalloprotease 15 Is Expressed on Rheumatoid Arthritis Synovial Tissue Endothelial Cells and Mediates Angiogenesis
Abstract Number: 958

Tumor Necrosis Factor-α Induces Production of Eotaxin-1/CCL11 from Fibroblast-like Synoviocyte in Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].